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Abstract 
Recent evidence suggests that the classic gut peptide, Peptide YY (PYY), could play a 
fundamental role in endocrine pancreatic function. In the present study expression of PYY and 
its NPY receptors on mouse islets and immortalised rodent and human beta-cells was examined 
together with the effects of both major circulating forms of PYY, namely PYY(1-36) and 
PYY(3-36), on beta-cell function, murine islet adaptions to insulin deficiency/resistance, as 
well as direct effects on cultured beta-cell proliferation and apoptosis. In vivo administration 
of PYY(3-36), but not PYY(1-36), markedly (p < 0.05) decreased food intake in overnight 
fasted mice. Neither form of PYY affected glucose disposal or insulin secretion following an 
i.p. glucose challenge. However, in vitro, PYY(1-36) and PYY(3-36) inhibited (p < 0.05 to p 
< 0.001) glucose, alanine and GLP-1 stimulated insulin secretion from immortalised rodent 
and human beta-cells, as well as isolated mouse islets, by impeding alterations in membrane 
potential, [Ca2+]i and elevations of cAMP. Mice treated with multiple low dose streptozotocin 
presented with severe (p < 0.01) loss of beta-cell mass accompanied by notable increases (p < 
0.001) in alpha and PP cell numbers. In contrast, hydrocortisone-induced insulin resistance 
increased islet number (p < 0.01) and beta-cell mass (p < 0.001). PYY expression was 
consistently observed in alpha-, PP- and delta-, but not beta-cells. Streptozotocin decreased 
islet PYY co-localisation with PP (p < 0.05) and somatostatin (p < 0.001), whilst 
hydrocortisone increased PYY co-localisation with glucagon (p < 0.05) in mice. More detailed 
in vitro investigations revealed that both forms of PYY augmented (p < 0.05 to p < 0.01) 
immortalised human and rodent beta-cell proliferation and protected against streptozotocin-
induced cytotoxicity, to a similar or superior extent as the well characterised beta-cell 
proliferative and anti-apoptotic agent GLP-1. Taken together, these data highlight the 
significance and potential offered by modulation of pancreatic islet NPY receptor signalling 
pathways for preservation of beta-cell mass in diabetes. 
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1. Introduction 
Cells of the pancreatic islets of Langerhans have a vital endocrine function related to secretion 
of hormones that regulate of glucose homeostasis and nutrient metabolism. The physiological 
significance of the classical islet peptide hormones including insulin, glucagon and 
somatostatin is already well established (Unger et al., 1978). More recently, the existence of 
other non-classical islet regulatory peptide hormones has been described (Heller and Aponte 
1995, Myrsen-Axcrona et al., 1997; Masur et al., 2005; Fujita et al., 2010; Hansen et al., 2011; 
Whalley et al., 2011, Marchetti et al., 2012). As such, ghrelin is now considered as a pancreatic 
islet hormone (Wierup et al., 2014), with an accepted function of regulating insulin secretion 
and blood glucose levels (Yada et al., 2014). In addition, the incretin peptides, namely glucagon 
like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), secreted 
locally from islet alpha-cells, have been shown to modulate beta-cell mass under situations of 
cellular stress (Moffett et al., 2014; Vasu et al., 2014; Moffett et al., 2015). Likewise, there is 
now emerging evidence to suggest that islet cell secretion and action of the gut hormone peptide 
YY (PYY), may be involved in the preservation of beta-cell mass and control of insulin 
secretion (Sam et al., 2012; Persaud and Bewick, 2014; Shi et al., 2015). In keeping with this, 
receptors that mediate the biological actions of PYY, namely neuropeptide Y (NPY) receptors, 
are thought to be expressed on pancreatic endocrine cells (Amisten et al., 2013). 
 PYY is a hormone that was first isolated from porcine gut in 1980, and shown to be 
closely related to pancreatic polypeptide (PP) (Tatemoto and Mutt, 1980). During embryonic 
development, the first islet cell type to appear is known to co-express glucagon and the PP 
family of peptides, including PYY (Mulder et al., 1998). This could suggest that PYY plays 
some part in beta-cell development, adaptation and ultimately insulin secretory function 
(Mulder et al., 1998). In agreement, selective destruction of PYY expressing cells in adult mice 
induces dysfunction and loss of beta-cells (Sam et al., 2012), whilst transgenic mice 
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overexpressing PYY have a tendency for increased insulin concentrations (Shi et al., 2012). 
Moreover, recent characterisation of transgenic mice selectively overexpressing PYY in 
pancreatic beta-cells revealed increased beta-cell mass and enhanced basal, but not glucose-
stimulated insulin release (Shi et al., 2015). Interestingly, PYY knockout (PYY-/-) mice exhibit 
hyperinsulinaemia (Boey et al., 2006), perhaps reflecting adaptive changes as a result of 
lifelong PYY deficiency. Taken together, it is apparent that modulation of PYY islet signalling 
could represent a potential new therapeutic approach to diabetes, which is typically 
characterised by a significant loss of beta-cell mass and function over time (Thorens, 2013). 
There are two well characterised circulating forms of PYY, PYY(1-36) and PYY(3-36) 
(Grandt et al., 1994). PYY(3-36), the main circulating form generated by DPP-4 action 
(Medeiros and Turner, 1994), is largely recognised as the major bioactive PYY peptide 
responsible for the well documented anorectic actions, including inhibition of food intake, 
reduced gastric motility and reduction in body weight gain (Greeley et al., 1988; Pittner et al., 
2004; Boey et al., 2007). However, at the pancreatic level PYY(1-36) has been shown in some 
studies to modulate insulin secretion from isolated rodent islets (Sam et al., 2012; Chandarana 
et al., 2013). Moreover, potential beneficial effects of PYY on pancreatic beta-cell survival 
may be linked to activation of NPY1 receptors, to which PYY(1-36) binds more strongly than 
PYY(3-36) (Sam et al., 2012). Therefore, in the present study we evaluated the effects of 
PYY(1-36) and PYY(3-36) on modulation of insulin section in vivo and in vitro from 
pancreatic clonal rodent BRIN BD11 and human 1.1B4 beta-cells, as well as mouse isolated 
islets. Furthermore, we assessed NPY receptor subtypes and potential mechanisms of PYY 
action on beta-cell insulin secretory function together with effects on beta-cell proliferation 
and apoptosis in vitro. Finally, we investigated whether changes in islet PYY expression are 
linked to the classical pancreatic architectural adaptations induced by streptozotocin and 
hydrocortisone treatment in mice. The results support the concept that PYY produced locally 
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within the islets may play an important role in the regulation of insulin secretion and 
preservation of beta-cell mass. 
 
2. Materials and methods 
2.1. Real time Reverse Transcription PCR  
To determine pancreatic expression of PYY and its receptors, namely NPY1, NPY2, NPY4 
and NPY5, mRNA was extracted from isolated mouse islets, clonal rodent BRIN BD11 cells 
and human 1.1B4 pseudoislets (Green et al., 2015) using an RNeasy Mini Kit following 
manufacturer’s instructions (Qiagen, UK). mRNA (3 µg) was converted to cDNA using 
SuperScript II Reverse Transcriptase kit (Invitrogen, Paisley, UK). The reaction mix consisted 
of Quantifast SYBR green master mix (Qiagen, UK), primers (forward and reverse), cDNA 
and RNase free water. Amplification conditions were set at 95°C for initial and final 
denaturation, 58°C for primer annealing and 72°C for extension for 40 cycles, followed by a 
melting curve analysis, with temperature range set at 60°C to 90°C. Data were analysed using 
ΔΔCt method and normalised to Actb/ACTB expression. 
 
2.2 Animals 
All animal studies were carried out using adult male C57BL/6 or NIH Swiss mice (12 weeks 
of age, Harlan Ltd, UK), housed individually in air conditioned room at 22±2°C with 12 hours 
light and dark cycle and ad libitum access to standard rodent diet (10% fat, 30% protein and 
60% carbohydrate; Trouw Nutrition, Northwich, UK) and drinking water. All in vivo 
experiments were carried out in accordance with the UK Animal Scientific Procedures Act 
1986.  
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2.3 Acute in vivo effects 
Plasma glucose and insulin responses were evaluated after intraperitoneal (i.p.) injection of 
glucose alone (18 mmol/kg body weight) or in combination with test peptides (25 nmol/kg body 
weight) in overnight (18 h) fasted NIH Swiss mice. In a second series of experiments, 18 h fasted 
normal mice were used to assess the effects of respective test peptides on food intake. Mice 
received an i.p. injection of saline alone (0.9 % (w/v) NaCl) or in combination with test peptides 
(25 nmol/kg body weight) and food intake measured at 30 min intervals. 
 
2.4 In vitro insulin secretion  
Effects of peptides on in vitro insulin secretion were examined using immortalised rodent BRIN-
BD11 and human 1.1B4 beta-cells, whose characteristics have been reported previously 
(McClenaghan et al., 1996; McCluskey et al., 2011). Importantly, BRIN-BD11 cells mimic the 
glucose sensitivity and overall secretory performance of other immortal beta-cell lines and 
represent a useful cellular model for studies of beta-cell function (Hamid et al., 2002). Cells were 
seeded (150,000/well) into 24-well plates (Nunc, Roskilde, Denmark) and allowed to attach 
overnight at 37°C. Following 40 min pre-incubation (1.1 mmol/L glucose; 37oC), cells were 
incubated (20 min; 37°C) in the presence of 5.6 or 16.7 mmol/L glucose, as appropriate, with a 
range of test peptide concentrations (10-12 to 10-6 M). The effects of PYY(1-36) and PYY(3-36) 
on alanine and GLP-1 induced insulin secretion was also examined in BRIN BD11 cells.  After 
20 min incubation, buffer was removed from each well and aliquots stored at -20°C prior to 
determination of insulin by radioimmunoassay (Flatt and Bailey, 1982). To determine potential 
NPY receptor involvement, BRIN BD11 cells were incubated at 16.7 mM glucose with PYY(1-
36) or PYY(3-36) (10-8 and 10-6 M) and either the specific NPY1 receptor antagonist BVD-10 (10-
6 M; Tocris Bioscience) or the specific NPY2 receptor antagonist BIIE 0246 (10-6 M; Tocris 
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Bioscience), and insulin secretion determined as described above. In addition, to determine 
potential mechanisms of action, membrane potential and intracellular Ca2+ were also determined 
following treatment with test peptides (10-6 M) in BRIN BD11 cells using a Flexstation scanning 
fluorometer (FLIPR Calcium 5 assay kit, FLIPR membrane potential assay kit, Molecular devices, 
Sunnyvale, USA) as described previously (Miguel et al., 2004). Furthermore, effects of PYY(1-
36) and PYY(3-36) on GLP-1 mediated elevations of intracellular cAMP were assessed in BRIN 
BD11 cells using a Parameter cAMP assay (R&D Systems, Abingdon, UK), according to the 
manufacturer’s instructions. In a separate series, pancreatic islets were isolated from lean control 
C57BL/6 mice by collagenase digestion, as described previously (Pathak et al., 2015). Insulin 
secretion was determined as above, but with a 60 min test incubation period. In one series of 
experiments the actions of GLP-1, PYY(1-36) and PYY(3-36) were examined in the absence and 
presence of the DPP-4 inhibitor sitagliptin (500 nM, ApexBio Technology, Houston, TX, USA). 
Following removal of the test solution, 200 µl of acid–ethanol solution (1.5% (v/v) HCl, 75% (v/v) 
ethanol, 23.5% (v/v) H2O) was added for overnight extraction of cellular insulin. All samples were 
stored at -20 °C for measurement of insulin concentrations by radioimmunoassay (Flatt and 
Bailey, 1982).  
 
2.5 Islet histology studies in insulin-deficient and insulin-resistant diabetic mice 
To induce insulin-deficient diabetes, multiple low dose streptozotocin (50 mg/kg body weight, 
i.p.) in 0.1 M sodium citrate buffer (pH 4.5) or saline vehicle (0.9% w/v NaCl, i.p.) was injected 
daily (13:00 h, n=6, fasted for 4 h) over a period of 5 days in C57BL/6 mice (Vasu et al., 2014). 
Pancreatic tissues were excised five days after the final injection. To induce insulin-resistant 
diabetes, hydrocortisone was injected i.p. (70 mg/kg body weight in saline, n=6) once daily 
over a period of 10 days in C57BL/6 mice, and pancreatic tissues extracted at the end of the 
treatment period (Vasu et al., 2014). All pancreatic tissues were immediately fixed in 4% PFA 
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for 48 h at 4°C and subsequently dehydrated using a series of increasing strength ethanol 
solutions and processed for embedding in paraffin wax using an automated tissue processor 
(Leica TP1020, Leica Microsystems, Nussloch, Germany), as described previously (Vasu et 
al., 2013; Moffett et al., 2013). Tissue blocks were sectioned (8 μm) using a Shandon Finesse 
325 microtome (Thermo Scientific, Hemel Hempstead, UK) and picked for staining at intervals 
of 10 sections. After deparaffinising, sections were rehydrated using a series of decreasing 
strength ethanol solutions. Antigen retrieval was carried out using a citrate buffer (pH 6.0) at 
94°C for 20 min, sections were then blocked using 2% BSA and incubated overnight at 4°C 
with appropriate primary antibody (Table 1). The slides were then incubated with appropriate 
secondary antibodies (Alexa Fluor® 594 for red and Alexa Fluor® 488 for green; Table 1) and 
stained with nuclear DAPI staining. Importantly, we confirmed the specificity of our PYY 
antibody in blocking experiments using the native PYY(1-36) peptide, and no cross-reactivity 
with PP was observed. Slides were mounted with anti-fade mounting medium and viewed using 
a fluorescent microscope (Olympus System Microscope, model BX51; Southend-on-Sea, UK). 
The slides were photographed using a DP70 camera adapter system (Vasu et al., 2013; Moffett 
et al., 2013). All staining procedures and image analysis were carried out in a blinded manner. 
Approximately 150 islets were analysed per group. Islet parameters were determined using the 
‘closed polygon’ tool in Olympus Cell^F analysis software. PYY expression in 
alpha/PP/somatostatin cells was determined by counting cells with PYY and 
glucagon/PP/somatostatin expression and expressed as % of total alpha/PP/somatostatin cells. 
Areas of insulin and glucagon positive cells were calculated using the closed Polygon tool in 
Cell^F software, and expressed as total islet area, µm2. 
 
2.6 Beta-cell proliferation and cellular stress studies 
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To assess the effects of PYY(1-36) and PYY(3-36) on rodent BRIN-BD11 and human 1.1B4 
cell proliferation, cells were seeded at a density of 150,000 cells per well and cultured overnight 
in the presence of PYY peptides (10-6 M), with GLP-1 (10-6 M) as a positive control. Cells 
were rinsed with PBS and fixed using 4 % paraformaldehyde. After antigen retrieval with 
citrate buffer at 95°C for 20 min, tissue was blocked using 2% BSA for 45 minutes. The slides 
were then incubated with rabbit anti-Ki-67 primary antibody, and subsequently with Alexa 
Fluor® 594 secondary antibody. Slides were viewed using fluorescent microscope (Olympus 
System Microscope, model BX51; Southend-on-Sea, UK) and photographed by DP70 camera 
adapter system. Proliferation frequency was determined in a blinded fashion and expressed as 
% of total cells analysed. Approximately 150 cells per replicate were analysed. For analysis of 
ability of PYY(1-36) and PYY(3-36) to protect against streptozotocin-induced DNA damage, 
BRIN-BD11 and 1.1B4 cells were seeded as above. Cells were then exposed to streptozotocin 
(5 mM) in the presence or absence of test peptides (10-6 M) for 2 hours, with GLP-1 (10-6 M) 
as positive control. Cells were then harvested and a comet assay was performed as described 
previously (Lees-Murdock et al., 2004). Resulting gels were stained using DAPI (4’, 6 – 
diamidino – 2 –phenylindole) (100 μg/ml) and slides were viewed under appropriate filter using 
an Olympus fluorescent microscope. Comet score software (Version 1.5) was used for the 
analysis of % tail DNA (100 cells per gel) and olive tail moment. 
 
2.7 Biochemical analyses  
Blood samples were collected from the cut tip on the tail vein of conscious mice at the time 
points indicated in the Figs. Blood glucose was measured directly using a hand-held Ascencia 
Contour blood glucose meter (Bayer Healthcare, Newbury, Berkshire, UK). For plasma insulin 
analysis, blood samples were collected into chilled fluoride/heparin glucose micro-centrifuge 
tubes (Sarstedt, Numbrecht, Germany) and immediately centrifuged using a Beckman 
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microcentrifuge (Beckman Instruments, Galway, Ireland) for 1 min at 13,000 x g and stored at 
-20 °C, prior to determination of insulin concentrations by a modified insulin 
radioimmunoassay (Flatt and Bailey, 1982). 
 
2.8 Statistical analysis 
Statistical analyses were performed using GraphPad PRISM software (Version 5.0). Values are 
expressed as mean±S.E.M. Comparative analyses between groups were carried out using a 
One-way ANOVA with Berferroni post hoc test or student’s unpaired t-test, as appropriate. 
The difference between groups was considered significant if p < 0.05. 
 
3. Results 
3.1 Expression of PYY and NPY receptor mRNA in BRIN BD11 beta-cells, isolated mouse islets 
and immortalised human beta-cell pseudoislets  
As shown in Figure 1, PYY was expressed in mouse islets at slightly increased levels compared 
to PP mRNA expression (Fig. 1A). Glucagon mRNA expression was significantly (p < 0.001) 
higher than the β–actin housekeeping gene, whereas PP and PYY expression was significantly 
(p < 0.05) lower (Fig. 1A). In terms of NPY receptor expression, all data were normalised to 
β-actin expression and then comparisons made against the classic islet receptor, GIPR (Fig. 
1B-D). As such, NPY1R mRNA expression was particularly abundant in all experimental 
models examined, with comparable or increased when compared to expression of GIPR (Fig. 
1B-D). NPYR5 was undetectable in cultured human 1.1B4 cells (Fig. 1D), and was also 
expressed at a relatively low (p < 0.05) levels in isolated mouse islets (Fig. 1B), but at higher 
(p < 0.01) levels in BRIN BD11 cells. In addition, NPY2R expression was also diminished (p 
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< 0.01 to p < 0.001) in mouse islets and 1.1B4 beta-cells compared to GIP R (Fig. 1B,D), with 
relatively similar levels to GIPR in BRIN BD11 cells (Fig. 1C). In general, the expression 
profile of NPYR1, 2 and 4 was similar in mouse islets and immortalised human 1.1B4 beta-
cells (Fig. 1B,D). Notably, expression levels of all NPYR’s and GIPR were elevated in BRIN 
BD11 cells when compared to the other experimental cellular models (Fig. 1C). In addition, 
both mouse islets and 1.1B4 cells had comparatively high expression levels on NPYR4 
compared to other NPYR’s, whereas this receptor subtype was expressed at relatively low 
levels in BRIN BD11 cells (Fig. 1C).    
 
3.2 Effects of PYY(1-36) and PYY(3-36) on glucose tolerance and food intake in mice  
Administration of 25 nmol/kg PYY(1-36) or PYY(3-36) to normal mice in combination with 
glucose had no significant effect on blood glucose levels (Fig. 2A,B). In agreement, 
corresponding plasma insulin levels were not significantly altered by PYY(1-36) or PYY(3-
36) (Fig. 2C,D). However, whilst PYY(1-36) did not affect feeding behaviour in overnight 
fasted mice, PYY(3-36) significantly (p < 0.05) reduced food intake at 120, 150 and 180 min 
post-injection (Fig. 2E).  
 
3.3 Effects of PYY(1-36) and PYY(3-36) on insulin release from rodent BRIN BD11 beta-cells, 
isolated mouse islets and immortalised human 1.1B4 beta-cells  
At both 5.6 and 16.7 mM glucose, KCl (30 mM), alanine (10 mM) and GLP-1 (10-6 M and 10-
8 M) significantly (p < 0.001) increased insulin release from BRIN BD11 cells, when compared 
to respective glucose controls (Fig. 3A,B). In contrast, all concentrations of PYY(1-36) or 
PYY(3-36) examined (10-10 to 10-6 M) did not significantly affect insulin release at 5.6 mM 
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glucose (Fig. 3A). However, both forms of PYY significantly inhibited glucose-stimulated 
(16.7 mM) insulin release, with the exception of 10-10 M PYY(3-36) (Fig. 3B). Essentially 
similar observations were made in 1.1B4 cells, including inhibition of glucose-stimulated 
insulin release (Fig. 3C). Incubation of PYY(1-36) with the NPY1 specific receptor antagonist 
BVD-10 completely reversed (p <0.001) the insulinostatic effect of PYY(1-36) at 16.7 mM 
glucose, whereas NPY2 receptor antagonism had no effect (Fig. 3D). Interestingly, BVD-10, 
and the NPY2 specific receptor antagonist, BII0246, both inhibited (p <0.05 to p <0.01) the 
insulinostatic actions of PYY(3-36) in BRIN BD11 cells at 16.7 mM glucose (Fig. 3D). PYY(1-
36) and PYY (3-36) also significantly (p < 0.05) inhibited GLP-1 induced insulin release from 
BRIN BD11 cells (Fig. 3E). Both forms of PYY significantly (p < 0.05 to p < 0.001) inhibited 
alanine-induced insulin release at concentrations of 10-9 to 10-6 M (Fig. 3F), but had no effect 
on alanine-induced insulin secretion at lower concentrations of 10-10 M (Fig. 3F). In harmony 
with findings from immortalised rodent and human beta-cells, both PYY(1-36) and PYY(3-36) 
(10-8 to 10-6 M) inhibited (p < 0.01 to p < 0.001) glucose-induced insulin secretion from isolated 
mouse islets (Fig. 3G).  Primary islets were also used to assess the effects of DPP-4 inhibition 
with 500 nM sitagliptin on the insulin-releasing actions of exogenous GLP-1 and PYY peptides 
(Fig. 3H). Sitagliptin enhanced (p < 0.05) insulin release at 5.6 mM (possibly by inhibiting 
degradation of islet GLP-1 and GIP (Vasu et al., 2014; Moffett et al., 2015) and potentiated (p 
< 0.05) GLP-1-induced insulin secretion (Fig. 3H). Most notably, sitagliptin increased (p < 
0.05) the inhibitory effect of PYY(1-36) on alanine-induced insulin release without affecting 
he inhibitory actions of PYY(3-36) (Fig. 3H). 
 
3.4 Effects of PYY(1-36) and PYY(3-36) on membrane potential, intracellular Ca2+ and cAMP 
levels in rodent BRIN BD11 cells 
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Alanine (10 mM) significantly (p < 0.05 to p < 0.001) increased cell membrane potential and 
[Ca2+]i in BRIN BD11 cells (Fig. 4A-D). The two forms of PYY partially inhibited (p < 0.05 
to p < 0.001) the positive effects of alanine on both membrane potential and [Ca2+]i (Fig. 4B,D). 
As expected, GLP-1 and forskolin markedly (p < 0.001) increased intracellular cAMP 
generation, whilst PYY(1-36) and PYY(3-36) significantly (p < 0.001) inhibited GLP-1 
induced elevations of cAMP (Fig. 4E). The batch of forskolin tested in these experiments 
evoked a relatively small increase of cAMP.  
 
3.5 Effects of insulin-deficiency and insulin-resistance on islet architecture and morphology  
Fig. 5A shows representative images of pancreatic islets from saline, streptozotocin and 
hydrocortisone treated C57BL/6 mice. Streptozotocin significantly reduced beta-cell area (p < 
0.01) but did not alter overall islet area (Fig. 5B,C). This appeared to be partly due to a marked 
(p < 0.001) increase of both alpha and PP cell areas compared to control mice (Fig. 5D,E). In 
contrast, hydrocortisone significantly (p < 0.001) enhanced both islet and beta-cell areas, but 
had no obvious effect on alpha and PP cell areas (Fig. 5B-E). Neither intervention affected 
PYY or delta cell area (Fig. 5F,G). Further to this, streptozotocin reduced (p < 0.05), and 
hydrocortisone increased (p < 0.01), the number of islets compared to saline control mice (Fig. 
5H). Interestingly, islet size distribution was unchanged in streptozotocin treated mice, whereas 
hydrocortisone significantly (p < 0.001 and p < 0.01; respectively) increased the proportion of 
medium and large sized islets, and reduced (p < 0.001) the number of smaller sized islets (Fig. 
5I). Representative images showing co-localisation of PYY with glucagon, PP or somatostatin 
in islets of control, streptozotocin and hydrocortisone treated mice are shown in Fig. 6A. 
Despite lack of effect of treatments on overall PYY cell area (Fig. 5G), distinct differences in 
islet cell populations expressing PYY were revealed. As such, hydrocortisone increased (p < 
14 
 
0.05) co-localisation of PYY with glucagon (Fig. 6B), while streptozotocin decreased (p < 
0.001 and p < 0.05; respectively) co-localisation of PYY with somatostatin and PP positively 
stained cells (Fig. 6C,D).  
 
3.6 Effects of PYY(1-36) and PYY(3-36) on immortalised rodent BRIN BD11 and human 1.1B4 
cell proliferation 
Exposure of BRIN BD11 or 1.1B4 cells to GLP-1, PYY(1-36) or PYY(3-36) at 10-6 for 16 h 
significantly (p < 0.05 to p < 0.01) increased proliferation frequency compared to control 
cultures (Fig. 7A,B). Intriguingly, the proliferative effects of GLP-1 and PYY(1-36) in BRIN 
BD11 cells appeared to be linked to decreased (p < 0.01) gene expression of Crebp, and 
unaltered Foxo1 and Pdx1 expression (Table 2). Although reductions in Pdx1 gene expression 
levels were noted with both GLP-1 and PYY(1-36) treatment, this failed to reach significance 
(Table 2). PYY(3-36) had no significant effect on the expression levels of Crebp, Foxo1 or 
Pdx1 (Table 2). Representative images of Ki67 stained BRIN BD11 and 1.1B4 cells under each 
culture condition are shown in Fig. 7C.  
 
3.7 Protective effects of PYY(1-36) and PYY(3-36) on streptozotocin-induced DNA damage in 
immortalised rodent BRIN BD11 and human 1.1B4 cells  
Streptozotocin (5 mM) significantly (p < 0.001) decreased both BRIN BD11 and 1.1B4 cell 
viability, which was almost fully countered by co-culture with GLP-1 (10-6 M), and partially 
countered in 1.1B4 cells by PYY(1-36) and PYY(3-36) (Fig. 8A,B). Streptozotocin also 
significantly (p < 0.001) increased % tail DNA and olive tail moment in both beta-cell lines 
(Fig. 8C-F). Culture of BRIN BD11 and 1.1B4 cells with either GLP-1, PYY(1-36) or PYY(3-
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36) reversed the detrimental effects of streptozotocin on % tail DNA and olive tail moment 
(Fig. 8C-F). However, notably in human 1.1B4 cells the beneficial effects of PYY(1-36) and 
PYY(3-36) on % tail DNA and olive tail moment were visibly superior to GLP-1 (Fig. 8D,F). 
Indeed, both forms of PYY returned % tail DNA to control levels following streptozotocin 
insult, whereas cells treated with GLP-1 still had significantly (p < 0.001) increase % tail DNA 
when compared to control cultures (Fig. 8D). In terms of gene expression, streptozotocin 
significantly (p < 0.05) reduced mRNA expression of Bcl2 without effecting transcription of 
Nfkb1 and Bax in BRIN BD11 cells (Table 2). GLP-1 and PYY(3-36) treatment increased Bcl2 
mRNA levels, and expression levels were not significantly different from control cultures  
(Table 2). PYY(1-36) treatment did not alter the reduced Bcl2 expression levels induced by 
streptozotocin (Table 2). In addition, PYY(1-36) reduced (p < 0.05) Nfkb1 mRNA levels, an 
effect which was not observed with any of the other treatment modalities (Table 2). None of 
the culture conditions significantly affected Bax expression levels (Table 2). Representative 
comet images from each culture condition in BRIN BD11 and 1.1B4 cells are shown in Fig. 
8G. 
 
4. Discussion 
The most widely accepted biological function of PYY, secreted from intestinal L-cells in 
response to feeding, is as an anorectic hormone that reduces food intake and subsequently body 
weight (Batterham et al., 2002). However, the expression and synthesis of PYY in murine islet 
cells, as shown here, and previously (Ali-Rachedi et al., 1984; Bottcher et al., 1993), suggests 
a possible important autocrine or paracrine role for this peptide hormone in regulating islet 
function.  
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As expected (Batterham and Bloom, 2003), PYY(3-36) significantly reduced food 
intake in overnight fasted mice in the current study, whereas PYY(1-36) was devoid of 
appetite-suppressive actions. This effect is linked to likely selectivity and high affinity of 
PYY(3-36) for NPY2 receptors, whereas PYY(1-36) is believed to bind to all NPY receptors 
(NPY1, 2, 4 and 5) with similar affinity (Grandt et al., 1992). Neither PYY(1-36) nor PYY(3-
36) altered circulating glucose or insulin levels in mice, suggesting that PYY released from the 
gut has little direct input on blood glucose control. However, both peptides evoked a notable 
reduction in glucose-stimulated insulin secretion from immortalised BRIN BD11 and human 
beta-cells, as well as isolated mouse islets. This apparent discrepancy between in vitro and in 
vivo observations may require further study, but in our view could simply be related to 
differences in concentrations of peptides exposed directly to islet cells. An insulinostatic action 
is largely in agreement with others (Szecowwka et al., 1983; Bottcher et al., 1989; Sam et al., 
2012), and importantly observed at concentrations of PYY greater than those encountered in 
the circulation (Murphy and Bloom, 2006). Nevertheless, such concentrations could potentially 
be encountered locally within islets as suggested by widespread PYY protein expression in 
alpha, delta and PP cells together with demonstration of mRNA for PYY at levels greater than 
the classical islet peptide PP. In contrast, it has recently been shown that chronic exposure of 
diabetic rat isolated islets to PYY restores insulin secretory function (Ramracheya et al., 2016). 
Moreover, in one report peripheral PYY(3-36) administration was revealed to augment insulin 
release and improve glucose homeostasis, albeit through an action believed to be dependent on 
GLP-1 secretion (Chandarana et al., 2013).  
Clearly further studies are required to fully assess the longer-term impact of both 
PYY(1-36) and PYY(3-36) on beta-cell insulin secretory function, but our data confirm an 
inhibitory insulinotropic effect upon acute exposure of beta-cells to either form of PYY. In 
agreement, we detected co-localisation of PYY with all murine islet cell types, except beta-
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cells. This is consistent with previous observations that PYY is not naturally expressed in adult 
mouse beta-cells (Upchurch et al., 1994; Sam et al., 2012). However, indicative of a role in 
beta-cell function, mouse islets and both immortalised human and rodent pancreatic beta-cells 
expressed NPY receptors at levels quite similar to GIPR, in accordance with GPCR screening 
studies (Amisten et al., 2013). Notably, the expression of all NPY receptors was elevated in 
BRIN BD11 cells, when compared to both mouse islets and immortalised human 1.1B4 beta-
cells, which may require further investigation and could also impact on some of our current 
observations. Others have struggled to evidence expression of NPY2 receptors in pancreatic 
islets cells (Chandarana et al., 2013), but we have clearly shown detectable amounts in isolated 
mouse islets, as well as immortalised rodent and human beta-cells in the present study. 
Quantification of mouse islet and human 1.1B4 cell NPY receptor mRNAs indicated 
that NPY1R and NPY4R were most abundant, with much lower expression of NPY2R and 
NPY5R. In fact, the latter was undetectable in immortalised human beta-cells. Of the various 
receptor subtypes, the NPY1 receptor has been suggested by others to be particularly important 
in regulation of islet function (Morgan et al., 1998; Amisten et al., 2013). Whilst BRIN BD11 
cells expressed high levels of NPY1R, the expression of NPY2R and NPY5R was also 
significant. These differences in NPY receptor mRNA levels between the cellular models used 
is interesting and requires further investigation. Nonetheless, the effects of PYY(1-36) and 
PYY(3-36) on insulin secretion were remarkably similar across all in vitro systems, arguing 
against a key role for NPY5 and possibly 4 receptors. Since PYY(3-36) is considered to be 
selective for NPY2 receptors, these results together with present demonstration of the NPY2 
receptor in various beta-cell preparations suggests that islet effects of PYY(3-36) may be 
mediated through this receptor subtype. However, we cannot entirely rule out mediation of 
effects via NPY1 receptors which bind PYY(3-36), albeit with weaker affinity (Karra et al., 
2009). Indeed, our preliminary in vitro studies in BRIN BD11 cells with selective NPY1 and 2 
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receptor antagonists support this concept. As such, beta-cell actions of PYY(1-36) appear to be 
solely mediated by NPY1 receptors, whereas PYY(3-36) actions were dependent on interaction 
with both NPY1 and 2 receptors.  Regrettably, data from NPY1 and 2 receptor knockout mice 
is clouded through significant influence of genetic background on phenotype (Zambello et al., 
2011), and the possibility that NPY1 receptors may regulate the expression of NPY2 receptors 
(Wittmann et al., 2005).  
Investigation of possible insulinostatic mechanisms of action of PYY revealed 
inhibition of the insulin-releasing effects of GLP-1 and alanine, together with reductions of 
GLP-1 induced cAMP production (Nieuwenhuizen et al., 1994), and alanine-induced changes 
of BRIN BD11 beta-cell membrane potential and [Ca2+]i. Thus, PYY appears to uncouple 
various insulin secretory signal transduction pathways in beta-cells. Since PYY(1-36) is a 
substrate for DPP-4 which is present in islets (Omar et al., 2014) it is not clear whether 
conversion to PYY(3-36) is significant in the normal intra-islet effects of PYY. However, our 
preliminary studies utilising a DPP-4 inhibitor suggest that PYY(1-36) is degraded in vitro by 
mouse islets and that inhibition of truncation to PYY(3-36) enhanced its action. Although, in 
our hands PYY(3-36) appeared to possess similar insulinostatic properties as PYY(1-36), these 
data suggest that PYY(1-36) and activation of receptors other than NPYR2 may be particularly 
important. Irrespective of the receptor subtype and mechanism involved, the insulinostatic 
actions of both forms of PYY could represent a physiologically relevant brake for locally 
produced islet PYY to limit excessive beta-cell stimulation, potential beta-cell exhaustion and 
ultimately loss of beta-cell mass. This is potentially therapeutically relevant because beta-cell 
rest has been shown to preserve long-term beta-cell function and improve overall enduring 
glycaemic control (Brown and Rother, 2008; Pathak et al., 2015), and is plausible mechanism 
for PYY-induced beneficial pancreatic actions. Therefore, we next assessed PYY islet 
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expression in both streptozotocin and hydrocortisone treated mice, to evaluate potential impact 
of locally produced PYY in situations of both islet cell destruction and growth, respectively. 
Streptozotocin and hydrocortisone treatment induced characteristic opposing changes 
in murine islet morphology, consistent with previous observations (Vasu et al., 2014). As such, 
streptozotocin reduced islet number and beta-cell area (Vasu et al., 2014), but also induced 
marked increases in the alpha and PP cell areas with no effect on delta cells, confirming that 
these cell types are resistant to streptozotocin-induced toxicity (Rombout et al., 1987; Vasu et 
al., 2015). Co-localisation studies in streptozotocin mice revealed that PP and delta cells had 
decreased co-expression with PYY, but alpha cell co-localisation was unaltered. Considering 
that alpha cell area was dramatically increased in these mice, with no change in PYY cell area, 
the data suggests a relative increase in PYY co-localisation with alpha cells. Interestingly, it 
has previously been indicated that alpha-cells may act as progenitors for beta-cells, particularly 
under situations of severe beta-cell loss (Chung and Levine, 2010). In agreement, 
hydrocortisone increased PYY co-localisation with glucagon, and was associated with an 
expansion of beta-cell mass. Use of selective PYY antagonists could help determine the exact 
role of PYY signalling on endocrine islet cell morphology following intervention with 
streptozotocin or hydrocortisone. Moreover, in the present study both PYY(1-36) and PYY(3-
36) significantly augmented beta-cell proliferation by immortalised rodent and human beta-
cells, at a comparable level to GLP-1 (Baggio and Drucker, 2007; Campbell and Drucker, 
2013). Mitogenic actions of PYY have previously been documented (Kazanjian et al., 2003), 
and linked to activation of phospholipase C and mitogen-activated protein kinases, leading to 
phosphorylation of ERK1/2 which is directly involved in gene transcription and cell 
proliferation (Hansel et al., 2001; Howell et al., 2007; Persaud and Bewick, 2014). 
Interestingly, neither form of PYY affected transcription of Foxo1 and Pdx1, transcription 
factors known to be involved in the maintenance of beta-cell function and survival (Bernardo 
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et al., 2008). It should also be recognised that proliferation studies were conducted in 
immortalised beta-cell lines that inherently would be in a hyperproliferative state. 
It has been proposed that PYY mainly protects against beta-cell loss by preventing 
apoptosis, rather than directly increasing proliferation (Sam et al., 2012). In the current study, 
both PYY(1-36) and PYY(3-36) partially protected BRIN BD11 and 1.14B beta-cells from 
streptozotocin-induced DNA damage, to a similar or superior degree, as observed with GLP-1 
(Thiriet et al., 2005). This is consistent with the notion that NPY receptor activation increases 
PKC epsilon activity, which has direct inhibitory role in apoptosis (Mannon, 2002). As such, a 
long-acting, NPY1 and NPY2 receptor specific, PYY analogue has been shown to reverse 
streptozotocin-induced beta-cell loss in mice (Sam et al., 2012). Surprisingly, streptozotocin 
treatment resulted only in a decrease of Bcl2 transcription in our study, with no effect on Bax 
or Nfkb1 expression, which could be linked to the duration of the study or the streptozotocin 
treatment regimen employed. GLP-1 and PYY(3-36) reversed this detrimental effect on Bcl2 
transcription, whereas co-culture with PYY(1-36) actually reduced Nfkb1 expression. Thus, the 
ability of PYY(1-36) to protect pancreatic beta-cells from apoptosis (Sam et al., 2012) could 
be linked to modulation of Nfkb1 related cell signalling pathways, which is intriguing and 
requires further detailed study (Eizirik et al., 2001). In addition, it would also be useful to 
determine if PYY(1-36) alters translocation of Nfkb1 to the nucleus, a key feature of Nfkb1 
signalling (Baeuerle, and Baltimore, 1996). 
Taken together, our combined observations along with recently published literature 
(Sam et al., 2012; Persaud and Bewick, 2014; Shi et al., 2015), provides evidence that PYY 
plays an essential role in regulating beta-cell function and preserving beta-cell mass. Given that 
beta-cell dysfunction and decreased beta-cell mass are classic features of both type 1 and type 
2 diabetes (Thorens, 2013), our data suggest that NPY receptor modulation could represent a 
novel target for the treatment, or prevention, of diabetes.   
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Table 1. Target, host and source of primary and secondary antibodies employed for 
immunoflourescent islet histology studies 
Primary antibodies 
 
 
 
 
 
 
 
 
 
 
Secondary antibodies 
Target Host Reactivity Dilution Fluorescent dye and Source 
IgG Goat Mouse 1:400 Alexa Flour 594, Invitrogen, UK 
IgG Goat Guinea pig 1:400 Alexa Flour 488, Invitrogen, UK 
IgG Goat Rabbit 1:400 Alexa Flour 594, Invitrogen, UK 
IgG Goat Rat 1:400 Alexa Flour 488, Abcam 
IgG Donkey Goat 1:400 Alexa Flour 488, Invitrogen, UK 
 
 
 
 
 
 
Target Host Dilution Source 
Insulin Mouse 1:500 Abcam, ab6995 
Glucagon Guinea pig 1:200 Raised in-house PCA2/4 
PYY Rabbit 1:500 Abcam, ab22663 
PP Goat 1:200 Abcam, ab77192 
SST Rat 1:500 Biorad, 8330-009 
Ki67 Rabbit 1:200 Abcam, ab15580 
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Table 2 Effects of PYY(1-36) and PYY(3-36) on expression of genes involved in 
proliferation and apoptosis. 
 
 
Gene expression for proliferation was assessed in BRIN BD11 beta-cells cultured with PYY 
peptides or GLP-1 (10-6 M) for 16 h. Gene expression for apoptosis was similarly assessed in 
BRIN BD11 cells exposed to 5 mM streptozotocin. Values are mean ± SEM (n=4). Gene 
expression was normalized to Actb expression. *p < 0.05, **p < 0.01 compared to untreated 
control. ND, not determined. 
 
 
 
 
 
 
 
Proliferation Control Streptozotocin 
(5 mM) 
GLP-1  
(10-6 M) 
PYY(1-36) 
(10-6 M) 
PYY(3-36) 
(10-6 M) 
1. Foxo1 
2. Pdx1 
3. Crebp 
100±14.09 
100±15.16 
100±10.75 
ND 
ND 
ND 
62.5±19.2 
87.3±60.0 
20.5±19.0** 
89.5±16.2 
50.0±16.1 
20.3±16.4** 
126.3±11.1 
74.7±15.8 
70.5±12.9 
Apoptosis Control Streptozotocin 
(5 mM) 
GLP-1 
(10-6 M) 
PYY(1-36) 
(10-6 M) 
PYY(3-36) 
(10-6 M) 
1. Nfkb1 
2. Bax 
3. Bcl2 
100±14 
100±9.8 
100±20.5 
94.2±16.1 
67±12.4 
43.4±9.9* 
111.3±12.2 
67.1±15.4 
57.5±15.9 
43.9±15* 
76.3±19.7 
24±12.9* 
50±16.3 
102.3±13.9 
49.1±20.6 
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Figure Legends 
Fig. 1. mRNA expression of PYY and NPYR. (A) PYY mRNA expression was compared to 
classical islet hormones glucagon, somatostatin and PP in mouse islets. (B-D) NPY receptor 
mRNA expression in (B) mouse islets, as well as immortalised (C) rodent and (D) human beta-
cell lines. Values are mean ± SEM (n = 4-6). (A) *p < 0.05, ***p < 0.001 compared to β-actin 
mRNA expression. (B) *p < 0.05, **p < 0.01, ***p < 0.001 compared to GIPR mRNA expression. 
All mRNA expression was normalized to Actb/ACTB expression. 
 
Fig. 2. Acute effects of PYY(1-36) and PYY(3-36) on glucose tolerance, insulin response to 
glucose and food intake in overnight fasted mice. (A) Blood glucose and (C) plasma insulin 
levels were assessed immediately before and after intraperitoneal administration of PYY(1-36) 
or PYY(3-36) (25 nmol/kg bw) together with glucose (18 mmol/kg bw).  Respective (B) blood 
glucose and (C) plasma insulin area under curve data is also shown. (E) Cumulative food intake 
was assessed after intraperitoneal administration of saline vehicle (0.9% NaCl), PYY(1-36) or 
PYY(3-36) (25 nmol/kg bw) in overnight fasted mice. Values are mean ± SEM (n=6 mice). *p 
< 0.05 compared to saline treated mice. 
 
Fig. 3. Effects of PYY(1-36) and PYY(3-36) on insulin release from immortalised rodent BRIN 
BD11 beta-cells, human 1.1B4 beta-cells and isolated mouse islets. (A,B) BRIN BD11 or (C) 
1.1B4 cells were incubated with either 5.6 or 16.7 mM glucose, as appropriate, and the effects 
of PYY peptides (10-10 – 10-6 M) determined. (D) Effects of selective NPY1 (BVD-10) and 
NPY2 (BII0246) receptor antagonists on PYY(1-36)- and PYY(3-36)-mediated insulin release 
from rodent BRIN BD11 beta-cells. Effects of PYY peptides on (E) GLP-1 (10-6 M) or (F) 
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alanine (10 mM) induced insulin release were also determined using BRIN BD11 cells. (G) 
Effects of PYY peptides (10-8 – 10-6 M) in isolated mouse islets. (H) Effects of sitagliptin (500 
nM) on the insulin secretory actions of GLP-1 (10-6 M) and ability of PYY peptides (10-6 M) 
to inhibit alanine-induced insulin secretion in isolated mouse islets. (A-F) Values are mean ± 
SEM (n=8). *p < 0.05, **p < 0.01, ***p < 0.001 compared to respective control. Δp < 0.05, ΔΔp 
< 0.01 compared to GLP-1. (G,H) Values are mean ± SEM (n=4). *p < 0.05, **p < 0.01, ***p < 
0.001 compared to 16.7 mM glucose. Δp < 0.05 to peptide in absence of sitagliptin. ϕϕϕp < 0.001 
compared to alanine. 
 
Fig. 4. Effects of PYY(1-36) and PYY(3-36) on membrane potential, [Ca2+]i and GLP-1-
induced cAMP production in rodent BRIN BD11 cells. (A,C) Cells were incubated with 5.6 
mM glucose in the presence of alanine (10 mM) or PYY peptides (10-6 M) and membrane 
potential or [Ca2+]i assessed over a 5 minute period, with alanine (10 mM) as positive control. 
(B,D) area under curve data is also shown. (E) BRIN BD11 cells were incubated (20 min) with 
GLP-1 (positive control; 10-6 M) in the absence and presence of PYY peptides (10-6 M) and 
intracellular cAMP was assessed by ELISA.  Values are mean ± SEM (n=6). **p < 0.01, ***p < 
0.001 compared to 5.6 mM glucose. Δp < 0.05, ΔΔp < 0.01, ΔΔΔp < 0.001 compared to respective 
positive control. 
 
Fig. 5. Effects of streptozotocin and hydrocortisone treatment on in vivo islet morphology and 
cells expressing PYY. C57BL/6 mice received daily injections of streptozotocin (50 mg/kg bw) 
or hydrocortisone (70 mg/kg bw) for 5 or 10 days respectively before examination of pancreatic 
histology on day 10. (A) Representative islet images showing insulin (red) and glucagon 
(green) staining in islets of control, streptozotocin and hydrocortisone treated mice. Nuclei are 
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demonstrated using DAPI staining (blue). Arrows indicate glucagon positive cells. (B) Islet, 
(C) beta-cell, (D) alpha cell, (E) PP cell, (F) delta cell and (G) PYY cell areas, as well as (H) 
number and (I) size distribution of islets, were determined using the ‘closed polygon’ tool in 
Olympus Cell^F analysis software.  Values are mean ± SEM (n=6 mice). *p < 0.05, **p < 0.01, 
***p < 0.001 compared to control mice.  
 
Fig. 6. Effects of streptozotocin and hydrocortisone treatment on co-localisation of PYY with 
glucagon, PP and somatostatin. C57BL/6 mice received daily injections of streptozotocin (50 
mg/kg bw) or hydrocortisone (70 mg/kg bw) for 5 or 10 days respectively before examination 
of pancreatic histology on day 10.  (A) Representative images showing PYY (red) staining with 
glucagon, PP and somatostatin (green) in islets of control, streptozotocin and hydrocortisone 
treated mice. Nuclei are demonstrated using DAPI staining (blue). Arrows indicate cells that 
are positive for both PYY and glucagon, PP or somatostatin. Quantification of co-localization 
of PYY with (B) glucagon, (C) PP and (D) and somatostatin is also shown. Values are mean ± 
SEM (n=6 mice). *p < 0.05, ***p < 0.001 compared to control mice. 
 
Fig. 7. Effects of PYY(1-36) and PYY(3-36) on immortalised rodent BRIN BD11 and human 
1.1B4 cell proliferation. (A,B) Proliferation frequency in (A) BRIN BD11 and (B) 1.1B4 cells 
cultured with PYY or GLP-1 (10-6 M) for 16 h. (C) Representative images showing 
proliferating beta-cells in the presence (16 h) of PYY or GLP-1 (10-6 M). Arrows indicate 
proliferating cells. Values are mean ± SEM (n=4). *p < 0.05, **p < 0.01 compared to control.   
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Fig. 8. Effects of PYY(1-36) and PYY(3-36) on protection of rodent BRIN BD11 cells from 
streptozotocin induced cellular stress. (A,B) Cell viability, (C,D) % tail DNA and (E,F) olive 
tail moment were assessed in response to 16 h exposure to 5 mM streptozotocin with and 
without co-culture with PYY or GLP-1 (10-6 M) in (A,C,E) BRIN BD11 and (B,D,F) 1.1B4 
beta-cells. (G) Representative images showing comets of control, streptozotocin alone and in 
combination with PYY or GLP-1 peptides (10-6 M) in both cell types. Arrows indicate cells 
with comet tails. Values are mean ± SEM (n=4). ***p < 0.01 compared to control. ΔΔp < 0.01, 
ΔΔΔp < 0.001 compared to streptozotocin treated cells.  
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